Company Description
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China.
The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient.
The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions.
In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes.
Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil’s chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth.
Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers.
BGM Group Ltd. is based in Chengdu, China.
| Country | China |
| Founded | 2019 |
| IPO Date | Jan 12, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Chen Xin |
Contact Details
Address: No.152 Hongliang East 1st Street, No. 1703, Tianfu New District Chengdu, 610200 China | |
| Phone | 86 28 6477 5180 |
| Website | bgmgroupltd.com |
Stock Details
| Ticker Symbol | BGM |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 1779578 |
| CUSIP Number | G7307E123 |
| ISIN Number | KYG7307E1237 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Li Hong | Co-Chief Executive Officer |
| Huandi Zhao | Co-Chief Executive Officer and Director |
| Yaxuan Zhai | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2026 | 6-K | Report of foreign issuer |
| Aug 11, 2026 | 6-K | Report of foreign issuer |
| Jul 30, 2026 | 6-K | Report of foreign issuer |
| Jul 28, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Jul 13, 2026 | 6-K | Report of foreign issuer |
| Jun 17, 2026 | 6-K | Report of foreign issuer |
| Jun 9, 2026 | 6-K | Report of foreign issuer |
| May 18, 2026 | 6-K | Report of foreign issuer |
| May 7, 2026 | 6-K | Report of foreign issuer |